Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS

• Published in: Annals of the American Thoracic Society Vol. 16; no. 2; pp. 200 - 208
• Main Authors: Ghosh, Sohini, Anderson, Wayne H, Putcha, Nirupama, Han, Meilan K, Curtis, Jeffrey L, Criner, Gerard J, Dransfield, Mark T, Barr, R Graham, Krishnan, Jerry A, Lazarus, Stephen C, Cooper, Christopher B, Paine, 3rd, Robert, Peters, Stephen P, Hansel, Nadia N, Martinez, Fernando J, Drummond, M Bradley
• Format: Journal Article
• Language: English
• Published: United States American Thoracic Society 01.02.2019
• Subjects: Administration, Inhalation; Adrenal Cortex Hormones - administration & dosage; Adrenergic beta-2 Receptor Agonists - adverse effects; Adrenergic beta-2 Receptor Agonists - therapeutic use; Aged; Asthma; Bronchodilator Agents - therapeutic use; Chronic obstructive pulmonary disease; Cohort Studies; Data collection; Disease Progression; Drug Therapy, Combination - adverse effects; Dyspnea; Family physicians; Female; Forced Expiratory Volume; Guideline Adherence - statistics & numerical data; Humans; Lung diseases; Male; Medical research; Middle Aged; Muscarinic Antagonists - adverse effects; Muscarinic Antagonists - therapeutic use; Original Research; Patient Compliance; Patients; Physicians; Pulmonary Disease, Chronic Obstructive - drug therapy; Questionnaires; Studies; inhaled therapy; treatment; chronic obstructive pulmonary disease
• ISSN: 2329-6933; 2325-6621
• DOI: 10.1513/AnnalsATS.201804-283OC

Despite awareness of chronic obstructive pulmonary disease (COPD) treatment recommendations, uptake is poor. The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) spans 2010-2016, providing an opportunity to assess integration of 2011 Global Initiative for Obstructive Lung Disease (GOLD) treatment strategies over time in a large observational cohort study. To evaluate how COPD treatment aligns with 2011 GOLD strategies and determine factors associated with failure to align with recommendations. Information on inhaled medication use collected via questionnaire annually for 4 years was compiled into therapeutic classes (long-acting antimuscarinic agent, long-acting β-agonist, inhaled corticosteroids [ICS], and combinations thereof). Medications were not modified by SPIROMICS investigators. 2011 GOLD COPD categories A, B, C, and D were assigned. Alignment of inhaler regimen with first-/second-line GOLD recommendations was determined, stratifying into recommendation aligned or nonaligned. Recommendation-nonaligned participants were further stratified into overuse and underuse categories. Of 1,721 participants with COPD, at baseline, 52% of regimens aligned with GOLD recommendations. Among participants with nonaligned regimens, 46% reported underuse, predominately owing to lack of long-acting inhalers in GOLD category D. Of the 54% reporting overuse, 95% were treated with nonindicated ICS-containing regimens. Among 431 participants with 4 years of follow-up data, recommendation alignment did not change over time. When we compared 2011 and 2017 recommendations, we found that 47% did not align with either set of recommendations, whereas 35% were in alignment with both recommendations. Among SPIROMICS participants with COPD, nearly 50% reported inhaler regimens that did not align with GOLD recommendations. Nonalignment was driven largely by overuse of ICS regimens in milder disease and lack of long-acting inhalers in severe disease.